시장보고서
상품코드
1741491

세계의 실데나필(Sildenafil) 의약품 시장 : 약물 유형별, 적응증별, 유통 채널별, 제형별, 지역별

Sildenafil Drug Market, By Drug Type, By Indication, By Distribution Channel, By Dosage Form, By Geography

발행일: | 리서치사: Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

실데나필 의약품 시장은 2025년에 33억 달러, 2032년에는 52억 달러에 이를 것으로 예측되며, 2025-2032년 연평균 복합 성장률(CAGR)은 6.7%를 나타낼 전망입니다.

보고서 범위 보고서 상세
기준 연도 2024 2025년 시장 규모 33억 달러
실적 데이터 2020-2024년 예측 기간 2025-2032년
예측 기간(2025-2032년) CAGR 6.70% 2032년 가치 예측 52억 달러

일반적으로 작은 파란색 알약으로 알려진 실데나필은 주로 발기부전(ED) 치료에 널리 사용되는 의약품입니다. 포스포디에스터라아제 5형(PDE5) 억제제라는 약효 분류에 속하며 비아그라라는 브랜드로 판매되고 있습니다. 실데나필은 음경 혈관의 평활근을 이완시켜 혈류를 증가시켜 궁극적으로 발기를 촉진합니다.

1990년대 후반에 도입된 이후, 실데나필은 발기부전 치료 분야에 혁명을 일으켜 전 세계 수백만 명의 남성에게 도움을 주었습니다. 실데나필은 발기력 유지에 어려움을 겪는 남성들이 의지할 수 있는 약물이 되었으며, 많은 사람들의 삶을 변화시키는 효과적인 해결책을 제공합니다.

시장 역학:

실데나필 의약품 시장은 예측 기간 동안 큰 성장을 이룰 것으로 예측됩니다. 이러한 성장을 가속하는 주요 요인으로는 전 세계 발기부전 유병률 증가, 고령화 인구 증가, 성 건강에 대한 인식 증가 등을 들 수 있습니다.

하지만, 시장에는 과제도 있습니다. 심각한 억제요인은 소비자에게 심각한 건강 위험을 초래할 수 있는 실데나필 제품의 위조품이 시장에 존재한다는 것입니다. 규제 기관과 제약회사는 위조 의약품을 단속하는 데 주력하고 있습니다.

이러한 어려움에도 불구하고, 실데나필 시장에는 몇 가지 기회가 있습니다. 구강붕해정이나 츄어블 정제와 같은 혁신적인 제형의 개발은 환자들에게 편의성과 복용의 용이성을 제공합니다. 실데나필 제네릭 의약품의 출현은 의약품을 보다 저렴하고 쉽게 구할 수 있게 함으로써 시장 성장을 가속할 것으로 예측됩니다.

본 조사의 주요 특징

  • 본 보고서는 2024년을 기준 연도로 하여 2025-2032년까지의 예측 기간 동안 시장 규모(US$ 10억 달러) 및 연평균 성장률(CAGR)을 포함한 실데나필 의약품 시장에 대해 상세하게 분석하였습니다.
  • 이 연구는 다양한 시장 부문에 걸친 잠재적 수익 기회를 탐색하고 이 시장에 대한 매력적인 투자 제안을 제시합니다.
  • 시장 성장 촉진요인, 저해요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 주요 고찰을 제공합니다.
  • 세계 실데나필(Sildenafil) 의약품 시장의 주요 기업 프로파일에 대해 분석했으며, 기업 배경, 제품 포트폴리오, 주요 실적, 재무 실적, 전략 등에 대해 조사하여 전해드립니다.
  • 이 보고서가 제공하는 통찰력을 통해 마케팅 담당자와 경영진은 제품 출시, 업그레이드, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
  • 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자들이 이 보고서의 통찰력을 통해 이익을 얻을 수 있을 것입니다.
  • 이해관계자들은 실데나필 의약품 시장 분석에 사용된 전략 매트릭스를 활용하여 의사결정 과정을 촉진할 수 있습니다.

목차

제1장 조사 목적과 전제조건

  • 조사 목적
  • 전제조건
  • 약어

제2장 시장 전망

  • 보고서 설명
    • 시장 정의와 범위
  • 주요 요약
  • Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
  • 주요 하이라이트
  • 규제 시나리오
  • 최근 동향
  • 제품 발매 및 승인
  • PEST 분석
  • PORTER 분석
  • 합병, 인수, 광고 협업

제4장 실데나필 의약품 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

  • COVID-19 역학
  • 공급측과 수요측 분석
  • 경제에 대한 영향

제5장 실데나필 의약품 시장, 약물 유형별, 2020년-2032년

  • 브랜드 의약품
  • 제네릭 의약품
  • 시판약

제6장 실데나필 의약품 시장, 적응증별, 2020년-2032년

  • 발기부전
  • 폐동맥 고혈압
  • 양성 전립선 비대증
  • 기타(조루, 고산병)

제7장 실데나필 의약품 시장, 유통 채널별, 2020년-2032년

  • 병원 약국
  • 소매 약국
  • 온라인 약국
  • 기타(클리닉, 통신판매 약국)

제8장 실데나필 의약품 시장, 제형별, 2020년-2032년

  • 정제
  • 경구 젤리
  • 주사
  • 기타(현탁액, 캡슐)

제9장 실데나필 의약품 시장, 지역별, 2020년-2032년

  • 북미
      • 미국
      • 캐나다
  • 유럽
      • 독일
      • 영국
      • 프랑스
      • 이탈리아
      • 스페인
      • 러시아
      • 기타 유럽
  • 아시아태평양
      • 중국
      • 인도
      • 일본
      • 호주
      • 한국
      • ASEAN
      • 기타 아시아태평양
  • 라틴아메리카
      • 브라질
      • 멕시코
      • 아르헨티나
      • 기타 라틴아메리카
  • 중동
      • GCC 국가
      • 이스라엘
      • 기타 중동
  • 아프리카
      • 남아프리카
      • 중앙아프리카
      • 북아프리카

제10장 경쟁 구도

  • 기업 개요
    • Pfizer
    • Teva Pharmaceuticals
    • Aurobindo Pharma
    • Alembic Pharmaceuticals
    • Torrent Pharmaceuticals
    • Lupin
    • Reddy's Laboratories
    • Zydus Cadila
    • Amneal Pharmaceuticals
    • Hetero
    • Apotex
    • Mylan
    • Ajanta Pharma
    • Sun Pharmaceutical
    • Cipla
    • Novartis
    • Eli Lily
    • Sanofi
    • Bayer
    • GlaxoSmithKline

제11장 섹션

  • 참고 문헌
  • 조사 방법
  • 출판사에 대해
LSH 25.06.19

Sildenafil Drug Market is estimated to be valued at USD 3.3 Bn in 2025 and is expected to reach USD 5.2 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 3.3 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 6.70% 2032 Value Projection: USD 5.2 Bn

Sildenafil which is commonly known as the little blue pill, is a widely used drug primarily used to treat erectile dysfunction (ED). It belongs to the class of medications called phosphodiesterase type 5 (PDE5) inhibitors and is marketed under the brand name Viagra. Sildenafil works by relaxing the smooth muscles of the blood vessels in the penis, thereby allowing for increased blood flow and ultimately facilitating an erection.

Since its introduction in the late 1990s, sildenafil has revolutionized the field of ED treatment, providing relief to millions of men worldwide. It has become the go-to medication for individuals experiencing difficulties in achieving and maintaining an erection, thereby offering an effective solution that has transformed the lives of many.

Market Dynamics:

The sildenafil drug market is expected to witness significant growth in the forecast period. The key drivers for this growth include the increasing prevalence of erectile dysfunction worldwide, the growing aging population, and the rising awareness regarding sexual health.

However, the market has also challenges. The significant restraint is the presence of counterfeit sildenafil products in the market, which can pose serious health risks to consumers. Regulatory bodies and pharmaceutical companies are making efforts to crack down on counterfeit drugs.

Despite these challenges, the sildenafil market presents several opportunities. The development of innovative dosage forms, such as orally disintegrating tablets and chewable tablets, offers convenience and ease of administration for patients. The emergence of generic versions of sildenafil is expected to drive the market growth by making the drug more affordable and accessible.

Key Features of the Study:

  • This report provides an in-depth analysis of the sildenafil drug market, including market size (in US$ Bn) and compound annual growth rate (CAGR %) for the forecast period of 2025-2032, with 2024 as the base year
  • The study explores potential revenue opportunities across different market segments and presents attractive investment propositions for this market
  • It offers key insights into market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • The report profiles key players in the global sildenafil drug market, highlighting their company background, product portfolio, key accomplishments, financial performance, and strategies
  • The study includes key companies such as Pfizer, Teva Pharmaceuticals, Aurobindo Pharma, Alembic Pharmaceuticals, Torrent Pharmaceuticals, Lupin, Dr Reddy's Laboratories, Zydus Cadila, Amneal Pharmaceuticals, Hetero, Apotex, Mylan, Ajanta Pharma, Sun Pharmaceutical, Cipla, Novartis, Eli Lily, Sanofi, Bayer, and GlaxoSmithKline.
  • The insights provided by this report would enable marketers and management authorities to make informed decisions regarding product launches, upgrades, market expansion, and marketing tactics
  • Various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts, would benefit from the findings of this report
  • Stakeholders can leverage the strategy matrices used in analyzing the sildenafil drug market to facilitate decision-making processes

Detailed Segmentation:

  • Sildenafil Drug Market, By Drug Type
    • Branded Drugs
    • Generic Drugs
    • Over The Counter Drugs
  • Sildenafil Drug Market, By Indication
    • Erectile Dysfunction
    • Pulmonary Arterial Hypertension
    • Benign Prostatic Hyperplasia
    • Others (Premature Ejaculation, Altitude Sickness)
  • Sildenafil Drug Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Others (Clinics, Mail Order Pharmacies)
  • Sildenafil Drug Market, By Dosage Form
    • Tablets
    • Oral Jellies
    • Injections
    • Others (Suspensions, Capsules)
  • Sildenafil Drug Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles
    • Pfizer
    • Teva Pharmaceuticals
    • Aurobindo Pharma
    • Alembic Pharmaceuticals
    • Torrent Pharmaceuticals
    • Lupin
    • Reddy's Laboratories
    • Zydus Cadila
    • Amneal Pharmaceuticals
    • Hetero
    • Apotex
    • Mylan
    • Ajanta Pharma
    • Sun Pharmaceutical
    • Cipla
    • Novartis
    • Eli Lily
    • Sanofi
    • Bayer
    • GlaxoSmithKline

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Indication
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Dosage Form
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Increasing prevalence of erectile dysfunction
    • Restraints
  • Adverse effects and safety concerns
    • Opportunities
  • Development of novel drug delivery system
  • Key Highlights
  • Regulatory Scenario
  • Recent Trends
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Mergers, Acquisitions, ad Collaborations

4. Sildenafil Drug Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Sildenafil Drug Market, By Drug Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Branded Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Generic Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Over The Counter Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Sildenafil Drug Market, By Indication, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Erectile Dysfunction
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Pulmonary Arterial Hypertension
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Benign Prostatic Hyperplasia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Others (Premature Ejaculation, Altitude Sickness)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Sildenafil Drug Market, By Distribution Channel, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Others (Clinics, Mail Order Pharmacies)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Sildenafil Drug Market, By Dosage Form, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Tablets
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Oral Jellies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Injections
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Others (Suspensions, Capsules)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Sildenafil Drug Market, By Region, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2021 -2032
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • U.S.
      • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
      • South Africa
      • Central Africa
      • North Africa

10. Competitive Landscape

  • Company Profile
    • Pfizer
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
    • Teva Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Aurobindo Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Alembic Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Torrent Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Lupin
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Reddy's Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Zydus Cadila
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Amneal Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Hetero
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Apotex
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
    • Mylan
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Ajanta Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Sun Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Cipla
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Novartis
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Eli Lily
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Bayer
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • GlaxoSmithKline
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Analyst Views

11. Section

  • References
  • Research Methodology
  • About us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제